IQVIA announced the launch of IQVIA MedTech and its dedicated industry focused solutions and services for the medical device and in vitro diagnostics market, and for companies with combination products. IQVIA MedTech empowers companies to orchestrate operations across their entire product lifecycle, from concept-to-market, providing quality control, regulatory, safety and compliance solutions along the way.
“We have served more than 800 MedTech clients in more than 70 countries by delivering an extensive suite of products, services and domain expertise for this space and for our customers’ needs,” said Bhavik Patel, senior vice president, IQVIA MedTech. “From helping our clients develop and execute clinical trials to entering new markets to managing regulatory processes, IQVIA MedTech supports a company’s individual needs worldwide.”
With access to cutting-edge technology and deep domain expertise, IQVIA MedTech breaks down silos across the product lifecycle and provides information at a geographic scale to drive expansion into global markets. Using innovative technology and tailored-consulting services, dedicated IQVIA MedTech account teams help companies address global implications of client compliance programs and develop strategies to keep pace within constantly evolving environments.
IQVIA MedTech’s comprehensive suite of Clinical to Commercial solutions including Integrated Global Compliance involving Regulatory Intelligence (RID), Regulatory Information Management (RIM) and Enterprise Quality Management (QMS) and Commercial Compliance provide for comprehensive regulatory and compliance needs. Additionally, MedTech products, managed services, and consulting offerings can help companies automate and address vigilance and safety processes. IQVIA MedTech offers a unique single-source alternative to disparate providers, yet integrates well with existing systems and processes.
IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With more than 58,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures.